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Background: Inhaled allergen challenge is a validated disease model of allergic asthma offering useful
pharmacodynamic assessment of pharmacotherapeutic effects in a limited number of subjects.
Objectives: To evaluate whether an RNA signature can be identified from induced sputum following an inhaled
allergen challenge, whether a RNA signature could be modulated by limited doses of inhaled fluticasone, and
whether these gene expression profiles would correlate with the clinical endpoints measured in this study.
Methods: Thirteen non-smoking, allergic subjects with mild-to-moderate asthma participated in a randomised,
placebo-controlled, 2-period cross-over study following a single-blind placebo run-in period. Each period
consisted of three consecutive days, separated by a wash-out period of at least 3 weeks. Subjects randomly
received inhaled fluticasone ((FP) MDI; 500 mcg BID5 doses in total) or placebo. On day 2, house dust mite
extract was inhaled and airway response was measured by FEV1 at predefined time points until 7 h post-
allergen. Sputum was induced by NaCl 4.5%, processed and analysed at 24 h pre-allergen and 7 and 24 h post-
allergen. RNAwas isolated from eligible sputum cell pellets (B80% squamous of 500 cells), amplified according
to NuGEN technology, and profiled on Affymetrix arrays. Gene expression changes from baseline and
fluticasone treatment effects were evaluated using a mixed effects ANCOVA model at 7 and at 24 h post-allergen
challenge.
Results: Inhaled allergen-induced statistically significant gene expression changes in sputum, which were
effectively blunted by fluticasone (adjusted pB0.025). Forty-seven RNA signatures were selected from these
responses for correlation analyses and further validation. This included Th2 mRNA levels for cytokines,
chemokines, high-affinity IgE receptor FCER1A, histamine receptor HRH4, and enzymes and receptors in
the arachidonic pathway. Individual messengers from the 47 RNA signatures correlated significantly with
lung function and sputum eosinophil counts.
Conclusion: Our RNA extraction and profiling protocols allowed reproducible assessments of inflammatory
signatures in sputum including quantification of drug effects on this response in allergic asthmatics. This
approach offers novel possibilities for the development of pharmacodynamic (PD) biomarkers in asthma.
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I
nhaled allergen challenge can be applied to study
the pathophysiology and the immune biology to
allergic stimuli within the airways. Allergen challenge
is highly reproducible and serves as an integral disease
model enabling the investigation of several features of
asthma (1). In drug development, allergen challenge
is an established tool predicting clinical efficacy of novel
anti-allergic and anti-asthma treatments (2). Hypertonic
saline-induced sputum (3) has been shown to yield re-
producible increases in inflammatory cells and biomarkers
$These authors have contributed equally to this work.
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following allergen-induced late asthmatic response (LAR)
(4) with subsequent response to novel and existing anti-
inflammatory therapies (2, 47).
Microarray technology allows to profile gene expres-
sion of the entire genome and has been widely applied
in several asthma studies (8, 9). A large majority of these
gene profiling studies involved tissue obtained from asth-
matics like airway epithelium (10, 11), bronchial biopsies
(12), or nasal mucosal cells (13). Although gene expression
has also been studied in fluids from asthmatics like blood
(14), broncho-alveolar lavage (15, 16), and induced
sputum (17), little is published on extensive gene expres-
sion profiling on induced sputum cells following allergen
challenge.
In this study, Affymetrix 2.0 microarray technology
was used to measure the gene expression levels of50,000
transcripts in induced sputum obtained from 13 allergic
asthmatics before and after allergen challenge. In a refined
set of 47 genes signatures, we aimed to study: 1) the
feasibility and reproducibility of quantification of gene
expression in induced sputum at 7 and 24 h post-challenge,
2) their reversibility after a short course of inhaled
fluticasone (FP) treatment, and 3) the correlation with
lung function and eosinophil measurements.
Methods
Study population and design
Thirteen non-smoking subjects with clinically stable,
mild-to-moderate allergic asthma (18) using only prn
short-acting beta2-agonists and with dual airway re-
sponses to inhaled house dust mite (HDM), documented
during the single-blind placebo run-in screening period,
participated in a double-blind, 2-way cross-over study.
Each period consisted of three consecutive days, with ]3
weeks wash-out between periods (Fig. 1). The screening
was identical to the subsequent treatment periods during
which subjects randomly received inhaled FP metered dose
inhaler (MDI; 500 mg BID, total of 5 doses) or matching
placebo. On day 1, baseline measurements, including
spirometry and subsequent sputum induction (35 min
NaCl 4.5%), were performed prior to study medication.
On day 2, 1 h post-study medication, subjects underwent
a titrated allergen challenge (1). The subsequent airway
response was repeatedly measured by FEV1 until 7 h post-
allergen. At 24 h post-allergen (day 3), test procedures were
repeated as on day 1. All test procedures were conducted
according to standardised, validated methods and at
the same time of the day (within 2 h) during the different
treatment periods (1, 1921).
A dual airway response to inhaled HDM extract
consisted of an early asthmatic response (EAR) and a
LAR, defined as a fall in FEV1 ]15% from baseline
occurring between 03 h and 37 h post-allergen,
respectively.
This study was part of an allergen study measuring
allergen-induced Th2-profile in sputum. Detailed infor-
mation from the same study on subject characteristics,
reproducible quantification of sputum cytokines and
chemokines, related allergen-induced airway responses,
Fig. 1. Study design. Overview of the single-blind placebo run-in period and double-blind cross-over study periods 1 and 2
(upper section). Overview of study assessments (lower section). Time zero is time of first study medication dosing. The single-
blind placebo run-in screening period and the subsequent study periods 1 and 2 were identical. IS: induced sputum.
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and their reversal by fluticasone, have been described in a
recent publication (7).
The study was approved by the Ethics Committee of
Leiden University Medical Center, Leiden, The Nether-
lands, and all participants gave a signed informed consent
(EUDRACT number 2007-003671-40).
Study medication
Fluticasone 250 mg/puff (Allen & Hanburys, Glaxo
Wellcome Ltd, Middlesex, UK) and matching placebo
(Armstrong Pharmaceuticals Inc., Canton, MA, USA,
packaged at Merck Frosst, Kirkland, Canada) were
supplied in identical MDIs and inhaled per single puff
through an Aerochamber (Volumatic, GlaxoSmithKline,
Zeist, The Netherlands).
Allergen challenge
The allergen challenge was performed using the 2 min
tidal breathing method that has been previously validated
(1). The run-in period served as a dose (range) finding
procedure, while during study periods 1 and 2, each
subject inhaled the same 2 or 3 cumulative doses of
the allergen extract that had caused a fall in FEV1 of at
least 15% from baseline during the run-in period.
Following diluent, incremental doubling concentrations
(7.812,000 BU/mL) of HDM extract (Dermatophagoides
pteronyssinus; SQ 503, ALK-BPT, ALK-Abello´, Almere,
The Netherlands) in phosphate-buffered saline (PBS)
were aerosolised by a calibrated jet-nebuliser (DeVilbiss
646, output 0.13 mL/min, Somerset, Pennsylvania,
USA) and inhaled at approximately 12 min intervals,
until the EAR was reached (defined as a decrease in
FEV1 of ]15% from post-diluent baseline within 1 h
post-allergen). Airway response to inhaled allergen was
measured by FEV1 in duplicate on a calibrated spirom-
eter (Vmax Spectra; Sensor Medics, Bilthoven, The
Netherlands) according to standard procedures (22), at
10, 20, 30, 45, 60, 90 and 120 min and then hourly until
7 h after the last allergen inhalation. The highest,
technically valid measurement was expressed as percen-
tage decrease from post-diluent baseline FEV1 and in-
cluded into the analysis.
Sputum induction, processing and analysis
Sputum induction was performed as previously described
(21, 23) using a DeVilbiss Ultraneb 2,000 ultrasonic
nebuliser (Tefa Portanje, Woerden, The Netherlands)
connected to a 100-cm-long plastic tube, with an internal
diameter of approximately 22 mm, connected to a two-
way valve (No.2700; Hans-Rudolf, Kansas City, MO,
USA) with a mouthpiece. Hypertonic saline (NaCl 4.5%)
was nebulised and inhaled through the mouth, with the
nose clipped, during three periods of 5 min. At approxi-
mately 7 min following each induction, spirometry was
performed as a safety measure.
The cell pellet was processed as a full sample according
to guidelines (21, 24). The processing took place within
2 h of collection. A DTT 0.1% solution (dithiothreitol,
Calbiochem, La Jolla, CA, USA) was mixed with a
protease inhibitor pill (Complete Protease Inhibitor Cock-
tail tablets, Roche Applied Science #11 697 498 001; 1 pill
per 50 mL of solution). The volume of the entire sputum
sample was determined and an equal amount of 0.1%
DTT/protease inhibitor solution was added. Subse-
quently, the sample was mixed with a pipette and placed
in a warm shaking bath for 15 min at 378C. The
homogenised mixture was centrifuged at 390G (1,500
rpm) during 10 min. The supernatant was removed.
To determine cell viability and the total cell count, the
cell pellet was re-suspended in 2 mL PBS and filtered;
50 mL of the suspension was mixed with 50 mL of Trypan
Blue. Total cell counts were determined in a counting
chamber (Bu¨rker; Omnilab 402521) using a cell counter
(Omnilab 7005333). Cytospin slides (50 mL/cytospin;
Shandon Cytospin 4, Thermon Electron Corporation,
Runcorn, UK) were prepared by diluting the cell suspen-
sion with PBS in order to obtain approximately 0.5106
cells per mL, and subsequently centrifuged for 3 min at
254 G. Differential cell counts of eosinophils, neutrophils,
lymphocytes, macrophages, epithelial and squamous cells
were performed on May-Gru¨nwald-Giemsa-stained cy-
tospins by a certified cytopathologist. In each sputum
sample, at least 500 nucleated cells, excluding squamous
cells, were counted twice and the average percentage of
each cell type was determined and expressed as percentage
of nonsquamous cells. If 80% of the cell count consisted
of squamous cells, the quality of the sputum sample was
judged unsatisfactory and was excluded from analysis.
The remaining suspension was centrifuged a second
time. The resulting cell pellet was re-suspended in 1 mL
of TRIzol† (Invitrogen, Cat. # 15596-018, Life Technol-
ogies, Carlsbad, California, USA). RNA was amplified
using WT-Ovation† amplification technology (NuGEN,
San Carlos, California, USA). The amplified material
was labelled and hybridised using a standard Affymetrix
protocol. Gene expression studies were performed using
the Rosetta/Merck Human RSTA Custom Affymetrix 2.0
microarray (Affymetrix, Santa Clara, California, USA)
containing 51,562 probe sets interrogating 50,159 human
transcripts predominantly from REFSEQ, GenBank,
dbEST and ENSEMBL databases as described on the
Gene Expression Omnibus website (www.ncbi.nlm.nih.
gov/geo/). The accuracy of sample processing was mon-
itored through quality metrics assessing RNA yield, RNA
quality: 18S/28S ribosomal RNA ratio, RNA integrity
number (RIN) score, and hybridisation parameters: 3?/5?
ratios for GAPDH mRNA and scale factor. In addition,
the amount of bacterial RNA contamination was evalu-
ated by calculating the area under the curve for the 16S and
23S (bacterial) versus the 18S and 28S (eukaryotic)
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ribosomal RNA peaks using a bio analyser electrophero-
grams (Agilent, Santa Clara, California, USA). Specimens
with more than 80% bacterial contamination were re-
moved from the analysis. Data were normalised using
the robust multichip average (RMA) algorithm prior to
statistical analysis.
Statistical model for data analysis
A mixed effect ANCOVA model was selected including
terms for baseline gene expression, treatment, sequence
and period as fixed effects and subject nested in sequence
as a random effect. Gene expression change from the
appropriate baseline was used as the dependent variable.
The baselines for each of the periods were used as
covariates.
Analysis of treatment effects
For each time point, 7 and 24 h, the allergen challenge
effect (ACE) and the FP treatment effect (FTE) were
calculated. The ACE was calculated as the change from
baseline when the subject received placebo treatment. The
FTE was calculated as the difference in change from
baseline between the FP treatment group and the placebo
group. p Values for each gene in each treatment effect
were adjusted using the BenjaminiHochberg’s procedure
with a false discovery rate (FDR) level pre-specified at
0.025 to select significant genes.
Correlation analyses
Pearson correlation coefficient and the associated p
value were computed for correlation between the estimated
individual subject-level effect, separately for ACE and
FTE, for a given clinical endpoint and gene of interest.
Assuming no period or sequence effect, subject-level ACE
was calculated as the log-transformed change from base-
line, for a clinical endpoint or gene of interest, when the
subject received placebo treatment. Similarly, subject-level
FTE was calculated as the difference in change from
baseline for a clinical endpoint or gene of interest when the
subject received fluticasone versus placebo. Type I error
of 10% (two-sided) was used to select significant results,
and no multiplicity adjustment was applied for declaring
statistical significance.
Results
Inhaled HDM induced both an EAR and an LAR in
all subjects during both placebo periods. Compared to
placebo, fluticasone significantly (pB0.001) reduced the
EAR and completely blunted the LAR (7).
Sputum samples were analysed from asthmatic subjects
who provided a baseline specimen in period 1 and period
2, and that passed the quality control (Table 1). Out of 13
subjects, nine had evaluable samples at both baselines. An
insufficient amount of human mRNA was the main cause
of sample exclusion, along with samples that did not meet
the criteria for matrix microarray quality control.
The reproducibility of the sputum induction and
collection procedures for RNA profiling after hybridisa-
tion on microarrays were evaluated by comparing in-
dividual gene expression intensities in combination with
hierarchical clustering using Pearson correlation coeffi-
cients (Fig. 2) (25). The results of this cluster analysis
revealed that 14 out of 18 sputum specimens clustered
appropriately in subject specific pairs, validating our
sputum collection and isolation protocol.
The whole microarray contained 51,562 probe sets.
At 7 h post-allergen challenge, and applying an FDR
ofB0.025, a total of 4.175 and 1.001 statistical significant
probe sets were identified for the allergen effect (ACE) and
the FTE, respectively. Likewise, 1.143 and 1.018 statistical
Table 1. Treatment allocation and sample quality results
Subject Run-in, 0 h Run-in, 7 h Run-in, 24 h Period 1, 0 h Period 1, 7 h Period 1, 24 h Period 2, 0 h Period 2, 7 h Period 2, 24 h
1 Baseline Placebo Placebo Baseline Placebo Placebo Baseline Fluticasone Fluticasone
2 Baseline Fail Placebo Fail Fluticasone Fail Baseline Fail Placebo
3 Baseline Placebo Placebo Baseline Fluticasone Fluticasone Baseline Placebo Placebo
4 Baseline Placebo Placebo Baseline Placebo Placebo Baseline Fluticasone Fluticasone
5 Baseline Placebo Placebo Baseline Placebo Placebo Baseline Fluticasone Fluticasone
6 Baseline Placebo Placebo Baseline Fluticasone Fluticasone Baseline Fail Placebo
7 Fail Fail Fail Fail Fail Fail Fail Fail Fail
8 Baseline Placebo Placebo Fail Fail Fluticasone Baseline Placebo Placebo
9 Fail Fail Fail Fail Fail Fail Fail Fail Fail
10 Baseline Placebo Placebo Baseline Placebo Placebo Baseline Fluticasone Fluticasone
11 Baseline Placebo Placebo Baseline Fluticasone Fluticasone Baseline Placebo Placebo
12 Baseline Placebo Fail Baseline Fail Placebo Baseline Fluticasone Fail
13 Baseline Placebo Placebo Baseline Fluticasone Fluticasone Baseline Placebo Placebo
Fail: the majority of failures was due to insufficient amount of human mRNA; few failures were because samples did not pass the matrix
microarray quality control.
Rob G.J.A. Zuiker et al.
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probe sets were identified at 24 h post-allergen for the
allergen effect and the FTE, respectively. Seven hundred
fourteen probes sets were regulated by both the ACE and
FP treatment at 7 h and 311 probe set at 24 h post-
challenge. All of the genes regulated by both the allergen
challenge and FP at each time point were reversed from
their allergen-induced levels in presence of fluticasone
(Fig. 3). In other words, fluticasone effectively blunted the
response to the allergen challenge at the gene expression
level.
Quantification of the individual genes that contribute to
the key mRNA levels for the Th1, Th2 and Th17 pathways
was performed by displaying the change from baseline in
gene expression at 7 and 24 h following allergen challenge
in presence or absence of FP treatment (Fig. 4). This
analysis revealed the up-regulation by the allergen chal-
lenge and the down-regulation by FP treatment of the
gene expression for several key Th2 mRNA levels for
interleukin (IL)-4, IL-5 and IL-13 and an absence of
an effect on key Th1 mRNA levels for interferon (INF)-g
and tumour necrosis factor (TNF). Chemokine ligand
13 (CCL13)/monocyte chemoattractant protein (MCP)-4
(26), CCL17/thymus and activation regulated chemokine
(TARC) (27) and CCL26/eotoxin-3 (28) are inflammatory
chemokines mediating Th2 cell recruitment and known
to be induced by IL-4. Their gene expressions were up-
regulated by the allergen challenge and down-regulated
by FP treatment following a similar pattern as the Th2
mRNA levels (Fig. 5). Likewise, the same pattern was
observed for genes belonging to pathways controlling the
release of inflammatory parameters like: HDC (histidine
decarboxylase) known to catalyse the production of
histamine (29); histamine receptor 4 HRH4 which is
specific for eosinophils and basophils (30); FCER1A,
the alpha subunit of the high-affinity IgE receptor which
directly binds IgE and through crosslinking induces
the release of preformed histamine and proteases as well
as the generation of leukotrienes and prostaglandins; the
messengers for the enzyme GGT5 (gamma-glutamyl
Fig. 2. Hierarchal cluster assessment for reproducibility of sputum microarray data.
Analysis included only subjects for which the baseline specimens at period 1 and 2 were available. Numbers refer to subject
numbers. Log 10 ratios of intensity estimates versus the average of all intensities are displayed. Magenta colour refers to probe
sets that are up-regulated in reference to the pool of all specimens analysed and cyan to the probe sets that are down-regulated.
Blue rectangles link specimens from the same subject that co-cluster on the dendrogram.
Fig. 3. Log 10 estimates of gene expression changes for
the significant genes identified from contrast analysis at
7 hours and 24 hours with an FDRB0.025. ACE: allergen
challenge effect, estimates of changes from baseline in the
placebo group. FTE: fluticasone effect, estimates of differ-
ences in change from baseline between the placebo and the
fluticasone groups.
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transferase 5, which converts leukotrienes C4 to D4) (31);
ALOX15 (15-lipoxygenase) and the receptor PTGER3
(prostaglandin receptor 3) were also up-regulated by the
allergen challenge and down-regulated by FP treatment. In
most of the cases, the fold change from baseline was higher
at 7 h versus 24 h and the p values smaller. This suggests
that the 7 h time point provides the most useful readouts
of the strict inflammatory response following an allergen
challenge.
In order to facilitate the correlation analyses, the
union of the genes affected by the allergen challenge and
fluticasone 7 or 24 h post-challenge was reduced to a set
of 47 RNA signatures based on statistical significance,
intensity of the change from baseline, biological relevance
and classified based on druggable structural and functional
categories (Table 2 and Fig. 6). All the genes represented in
the 47 RNA signatures harbour robust expression changes,
and the large majority of them is up-regulated after 7 h
with the exception of FLT3 and CRLF2, which are
regulated only after 24 h.
The 47 RNA signature set was then used to identify
genes correlating with lung function measurements
(Table 3) and eosinophil cell counts and percentages
(Table 4). Allergen challenge and FP treatment-mediated
correlations were independently assessed for each probe set
in the signature by estimating correlations at the subject
level at 7 and 24 h post-allergen challenge. Correlation
plots for the most significant probe sets from each
Fig. 4. Fold change from baseline in gene expression. Th2 mRNA levels (IL4, IL5, IL13), Th1 mRNA levels (IFNG and TNF),
Th17 mRNA levels (IL22, IL26). Fold change from baseline for the placebo group is represented in red. Fold change from
baseline for the fluticasone group is represented in blue. p Values are adjusted p values; error bars represent 90% confidence
intervals.
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correlation analysis type are represented in Fig. 7. High
correlation for some of the probe sets, for example,
IL1RL1 and HRH4, and the eosinophil counts from the
allergen challenge and the fluticasone treatment effect
were observed, with correlation coefficients greater than
0.9 and p value betweenB0.001 and 0.002. In the ACE
analysis, probe sets for NRG1, CCR2, CD1C, MAP2K6,
IL26 were negatively correlated with FEV1 measurements
at 7 h. In the fluticasone treatment effect, probe sets for
NRG1, RUNX3, FLT3 were negatively correlated to the
FEV1 measurements at 7 and 24 h. NRG1 was the most
significant gene consistently negatively correlated to lung
function measurements at 7 h in both the allergen effect
and the fluticasone effect analysis with p values of and
coefficients of correlations in the range of 0.75 (p 0.054)
to 0.90 (p 0.002).
Discussion
In this study, a RNA signature in sputum induced by the
allergen challenge and reversed with fluticasone was
identified. A subset of these genes, known to regulate the key
inflammatory responses associated with allergic asthma,
correlated with clinical endpoints and may constitute
potential PD biomarkers of response to fluticasone.
Th2 responses have been traditionally described as
playing a central role in the pathophysiology of asthma,
although not all patients share a Th2 inflammatory pattern
(32). It is striking that in our study the shift toward the
Fig. 5. Fold change from baseline in gene expression. Inflammatory chemokines (CCL13, CCL17, CCL26), molecules controlling
the release of histamine (HDC, HRH4, FCER1A) prostaglandins and leukotrienes (PTGER3, ALOX15, GGT5). Fold change
from baseline for the placebo group is represented in red. Fold change from baseline for the fluticasone group is represented in
blue. p Values are adjusted p values; error bars represent 90% confidence intervals.
Sputum RNA signature in allergic asthmatics
Citation: European Clinical Respiratory Journal 2016, 3: 31324 - http://dx.doi.org/10.3402/ecrj.v3.31324 7
(page number not for citation purpose)
Table 2. Change from baseline in the placebo and the prednisone group for the 47 RNA signatures
Point estimate (90% confidence interval)
Probe set Gene symbol Houra
Fold change over baseline in
placebo group (P)
Fold change over baseline
in fluticasone group (F) F/P
Th2 cytokines
100125222_TGI_at IL13 7 8.08 (5.92, 11.01) 0.95 (0.71, 1.28) 0.12 (0.08, 0.18)
24 2.64 (2.03, 3.43) 0.76 (0.55, 1.03) 0.29 (0.19, 0.44)
100135525_TGI_at IL5 7 6.81 (4.08, 11.38) 0.56 (0.34, 0.91) 0.08 (0.04, 0.16)
24 3.77 (2.39, 5.93) 0.25 (0.15, 0.41) 0.07 (0.03, 0.12)
100136820_TGI_at IL4 7 6.1 (4.48, 8.3) 0.99 (0.74, 1.32) 0.16 (0.1, 0.25)
24 1.69 (1.3, 2.19) 0.88 (0.64, 1.19) 0.52 (0.34, 0.79)
100142120_TGI_at IL9 7 4.57 (2.94, 7.11) 1.23 (0.8, 1.88) 0.27 (0.17, 0.43)
24 1.84 (1.24, 2.73) 1.03 (0.66, 1.62) 0.56 (0.36, 0.87)
Chemokines and chemokine receptors
100124067_TGI_at CCR2 7 1.47 (1.22, 1.77) 1.09 (0.91, 1.3) 0.74 (0.59, 0.93)
24 1.24 (1.04, 1.47) 1.02 (0.84, 1.23) 0.82 (0.65, 1.03)
100142511_TGI_at CCL26 7 9.41 (6.47, 13.68) 1.3 (0.91, 1.85) 0.14 (0.09, 0.22)
24 2.21 (1.6, 3.05) 0.99 (0.68, 1.43) 0.45 (0.29, 0.7)
100147484_TGI_at CCR2 7 3.25 (2.19, 4.84) 0.79 (0.54, 1.15) 0.24 (0.16, 0.37)
24 1.95 (1.36, 2.79) 0.6 (0.4, 0.9) 0.31 (0.2, 0.47)
100148726_TGI_at CCL17 7 14.44 (8.76, 23.79) 2.21 (1.38, 3.56) 0.15 (0.08, 0.28)
24 6.75 (4.38, 10.4) 1.89 (1.14, 3.12) 0.28 (0.16, 0.49)
100159583_TGI_at CCL13 7 3 (2.42, 3.71) 1.17 (0.96, 1.44) 0.39 (0.3, 0.51)
24 2.53 (2.1, 3.04) 1.23 (0.99, 1.52) 0.49 (0.37, 0.63)
100302551_TGI_at CCL26 7 15.7 (9.93, 24.84) 1.45 (0.93, 2.24) 0.09 (0.05, 0.16)
24 3.34 (2.23, 5) 0.89 (0.56, 1.41) 0.27 (0.16, 0.45)
100303601_TGI_at CCR2 7 2.32 (1.67, 3.22) 0.92 (0.67, 1.26) 0.4 (0.26, 0.6)
24 1.6 (1.19, 2.14) 0.85 (0.61, 1.18) 0.53 (0.36, 0.79)
Enzymes and signalling molecules in prostaglandin, leukotriene pathways
100124660_TGI_at GGT5 7 4.92 (3.47, 6.98) 1.25 (0.9, 1.75) 0.25 (0.17, 0.39)
24 2.64 (1.95, 3.58) 0.91 (0.64, 1.29) 0.34 (0.23, 0.51)
100156386_TGI_at PTGS1 7 2.11 (1.66, 2.68) 0.64 (0.51, 0.8) 0.3 (0.22, 0.41)
24 2.04 (1.66, 2.5) 0.54 (0.43, 0.69) 0.27 (0.2, 0.35)
100157709_TGI_at ALOX15 7 5.27 (3.29, 8.43) 0.47 (0.3, 0.74) 0.09 (0.05, 0.18)
24 4.57 (3.08, 6.8) 0.53 (0.33, 0.85) 0.12 (0.06, 0.22)
100159242_TGI_at PTGS1 7 1.41 (1.19, 1.68) 0.68 (0.58, 0.8) 0.48 (0.38, 0.61)
24 1.54 (1.33, 1.77) 0.65 (0.55, 0.78) 0.42 (0.34, 0.53)
100309708_TGI_at PTGS1 7 2.03 (1.6, 2.57) 0.65 (0.52, 0.81) 0.32 (0.23, 0.44)
24 2.01 (1.65, 2.45) 0.54 (0.42, 0.68) 0.27 (0.2, 0.36)
FcERI and histamine signalling
100143473_TGI_at HDC 7 9.98 (6.15, 16.2) 0.9 (0.57, 1.43) 0.09 (0.05, 0.18)
24 2.92 (1.92, 4.46) 0.48 (0.29, 0.78) 0.16 (0.09, 0.31)
100161010_TGI_at HRH4 7 6.36 (4.29, 9.43) 1 (0.69, 1.44) 0.16 (0.09, 0.27)
24 1.42 (1.01, 1.98) 0.79 (0.53, 1.17) 0.56 (0.34, 0.92)
100161919_TGI_at HRH4 7 5.46 (3.51, 8.5) 1.09 (0.72, 1.66) 0.2 (0.11, 0.35)
24 1.46 (1, 2.14) 0.7 (0.45, 1.09) 0.48 (0.28, 0.83)
100138809_TGI_at FCER1A 7 5.46 (3.36, 8.88) 0.86 (0.54, 1.36) 0.16 (0.09, 0.28)
24 4.06 (2.68, 6.17) 0.48 (0.3, 0.78) 0.12 (0.07, 0.21)
100153603_TGI_at FCER2 7 4.55 (3.55, 5.83) 1.29 (1.01, 1.63) 0.28 (0.21, 0.39)
24 1.86 (1.5, 2.31) 0.96 (0.75, 1.23) 0.52 (0.38, 0.7)
Membrane-bound glycoproteins
100135727_TGI_at CD1A 7 3.07 (1.83, 5.17) 0.55 (0.34, 0.9) 0.18 (0.09, 0.35)
24 7.79 (4.99, 12.15) 0.63 (0.37, 1.05) 0.08 (0.04, 0.15)
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Table 2 (Continued )
Point estimate (90% confidence interval)
Probe set Gene symbol Houra
Fold change over baseline in
placebo group (P)
Fold change over baseline
in fluticasone group (F) F/P
100136515_TGI_at CD209 7 4.53 (3.42, 6.01) 0.97 (0.75, 1.27) 0.21 (0.15, 0.31)
24 1.89 (1.47, 2.42) 0.85 (0.64, 1.13) 0.45 (0.32, 0.64)
100139590_TGI_at CD200R1 7 5.69 (4.19, 7.73) 1.56 (1.17, 2.09) 0.27 (0.19, 0.4)
24 1.96 (1.51, 2.55) 0.8 (0.59, 1.09) 0.41 (0.29, 0.59)
100140890_TGI_at CD200R1 7 3.52 (2.5, 4.95) 1.44 (1.04, 1.98) 0.41 (0.26, 0.65)
24 1.3 (0.98, 1.74) 0.61 (0.43, 0.86) 0.47 (0.3, 0.73)
100142202_TGI_at CD1B 7 3.96 (2.45, 6.41) 0.57 (0.36, 0.89) 0.14 (0.07, 0.28)
24 10.17 (6.76, 15.31) 0.68 (0.42, 1.11) 0.07 (0.03, 0.13)
100143809_TGI_at CD207 7 3.96 (2.46, 6.38) 0.78 (0.5, 1.23) 0.2 (0.11, 0.35)
24 4.58 (3.03, 6.91) 0.64 (0.4, 1.03) 0.14 (0.08, 0.24)
100145467_TGI_at CD1C 7 3.4 (2.38, 4.86) 0.89 (0.64, 1.25) 0.26 (0.16, 0.42)
24 4.82 (3.57, 6.51) 0.78 (0.55, 1.12) 0.16 (0.1, 0.25)
100161022_TGI_at CD1C 7 2.96 (1.95, 4.52) 0.68 (0.45, 1) 0.23 (0.13, 0.4)
24 5.37 (3.76, 7.66) 0.59 (0.39, 0.9) 0.11 (0.06, 0.19)
100301303_TGI_at CD200R1 7 1.34 (1.19, 1.52) 1.03 (0.91, 1.15) 0.76 (0.64, 0.91)
24 1.05 (0.95, 1.17) 0.86 (0.76, 0.97) 0.81 (0.69, 0.96)
100303713_TGI_at CD209 7 1.07 (0.99, 1.15) 1.03 (0.96, 1.1) 0.96 (0.87, 1.06)
24 1.04 (0.97, 1.11) 1.03 (0.95, 1.11) 0.99 (0.9, 1.09)
100311406_TGI_at CD1C 7 3.01 (1.93, 4.68) 0.65 (0.43, 0.98) 0.22 (0.12, 0.39)
24 5.36 (3.69, 7.78) 0.61 (0.39, 0.95) 0.11 (0.07, 0.2)
Other cytokines, growth factors and their receptors
100122002_TGI_at IL32 7 1.7 (1.3, 2.24) 0.67 (0.52, 0.87) 0.39 (0.29, 0.54)
24 1.41 (1.11, 1.79) 0.53 (0.4, 0.7) 0.38 (0.28, 0.51)
100122958_TGI_at TNFRSF4 7 3.69 (2.51, 5.41) 0.81 (0.56, 1.18) 0.22 (0.15, 0.33)
24 2.63 (1.86, 3.71) 0.74 (0.5, 1.09) 0.28 (0.19, 0.42)
100127751_TGI_at NRG1 7 1.4 (1.23, 1.6) 1.11 (0.99, 1.26) 0.79 (0.66, 0.96)
24 1.26 (1.13, 1.41) 0.93 (0.81, 1.05) 0.73 (0.61, 0.88)
100130857_TGI_at TNFRSF10D 7 3.87 (2.74, 5.48) 1.28 (0.92, 1.78) 0.33 (0.21, 0.51)
24 1.37 (1.01, 1.86) 0.83 (0.59, 1.18) 0.61 (0.4, 0.93)
100134267_TGI_at CRLF2 7 1.42 (1.1, 1.83) 0.97 (0.76, 1.23) 0.68 (0.49, 0.96)
24 2.3 (1.86, 2.85) 0.96 (0.75, 1.24) 0.42 (0.3, 0.58)
100136439_TGI_at FLT3 7 1.14 (0.82, 1.57) 1.29 (0.94, 1.78) 1.14 (0.82, 1.57)
24 2.59 (1.92, 3.49) 1.3 (0.93, 1.8) 0.5 (0.37, 0.68)
100144830_TGI_at IL32 7 1.77 (1.38, 2.28) 0.66 (0.52, 0.84) 0.37 (0.28, 0.49)
24 1.47 (1.18, 1.84) 0.56 (0.43, 0.72) 0.38 (0.29, 0.49)
100147358_TGI_at IL22 7 4.86 (2.64, 8.92) 0.86 (0.48, 1.53) 0.18 (0.09, 0.33)
24 2.32 (1.34, 4.02) 0.71 (0.39, 1.3) 0.3 (0.17, 0.56)
100148162_TGI_at IL1RL1 7 3.88 (2.17, 6.91) 1.16 (0.68, 2) 0.3 (0.14, 0.65)
24 2.04 (1.25, 3.33) 1.06 (0.59, 1.88) 0.52 (0.25, 1.07)
100148210_TGI_at IL1RL1 7 2.58 (1.74, 3.81) 1.05 (0.72, 1.52) 0.41 (0.25, 0.67)
24 1.73 (1.24, 2.42) 0.72 (0.49, 1.06) 0.42 (0.26, 0.67)
100150696_TGI_at NRG1 7 4.6 (3.08, 6.86) 1.23 (0.84, 1.79) 0.27 (0.16, 0.44)
24 4.37 (3.1, 6.18) 0.75 (0.51, 1.12) 0.17 (0.11, 0.28)
100153634_TGI_at GPR171 7 3.01 (2.12, 4.29) 0.92 (0.66, 1.29) 0.3 (0.2, 0.45)
24 1.98 (1.45, 2.71) 1.06 (0.74, 1.52) 0.54 (0.36, 0.79)
100156398_TGI_at P2RY6 7 2.79 (2.03, 3.83) 1.08 (0.8, 1.46) 0.39 (0.27, 0.55)
24 2.29 (1.73, 3.03) 0.79 (0.57, 1.08) 0.34 (0.25, 0.48)
100159528_TGI_at IL26 7 4 (2.73, 5.85) 0.8 (0.56, 1.14) 0.2 (0.12, 0.33)
24 1.7 (1.23, 2.35) 0.63 (0.43, 0.93) 0.37 (0.23, 0.6)
100300593_TGI_at NRG1 7 4.1 (2.81, 5.98) 1.24 (0.87, 1.77) 0.3 (0.19, 0.47)
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Point estimate (90% confidence interval)
Probe set Gene symbol Houra
Fold change over baseline in
placebo group (P)
Fold change over baseline
in fluticasone group (F) F/P
24 3.88 (2.79, 5.4) 0.71 (0.49, 1.04) 0.18 (0.12, 0.28)
100302151_TGI_at IL1RL1 7 2.05 (1.4, 3) 1.08 (0.75, 1.55) 0.53 (0.33, 0.85)
24 1.36 (0.99, 1.89) 1.07 (0.73, 1.57) 0.78 (0.5, 1.24)
100302360_TGI_at NRG1 7 1.12 (1.01, 1.24) 1.08 (0.98, 1.19) 0.97 (0.84, 1.11)
24 1.1 (1.01, 1.19) 0.98 (0.89, 1.08) 0.89 (0.78, 1.02)
100302727_TGI_at NRG1 7 1.13 (1.03, 1.25) 1.06 (0.97, 1.17) 0.94 (0.82, 1.07)
24 1.04 (0.95, 1.13) 0.94 (0.86, 1.04) 0.91 (0.8, 1.04)
100302783_TGI_at IL1RL1 7 8.29 (4.53, 15.16) 1.44 (0.82, 2.54) 0.17 (0.08, 0.39)
24 2.75 (1.65, 4.59) 1.09 (0.6, 2) 0.4 (0.18, 0.86)
100302830_TGI_at TNFRSF4 7 2.81 (2.02, 3.9) 1.09 (0.79, 1.49) 0.39 (0.26, 0.58)
24 2.05 (1.55, 2.73) 0.83 (0.6, 1.16) 0.41 (0.28, 0.6)
100309572_TGI_at FLT3 7 1.22 (0.91, 1.64) 0.97 (0.74, 1.27) 0.79 (0.54, 1.17)
24 2.75 (2.15, 3.51) 1.11 (0.83, 1.5) 0.41 (0.28, 0.59)
100310066_TGI_at IL32 7 1.78 (1.32, 2.4) 0.61 (0.46, 0.82) 0.35 (0.24, 0.49)
24 1.51 (1.16, 1.96) 0.47 (0.35, 0.64) 0.31 (0.22, 0.44)
100312593_TGI_at NRG1 7 1.11 (0.96, 1.27) 0.99 (0.87, 1.13) 0.89 (0.75, 1.06)
24 0.95 (0.85, 1.07) 0.92 (0.8, 1.06) 0.97 (0.82, 1.14)
100312840_TGI_at IL1RL1 7 4.69 (2.56, 8.58) 1.2 (0.68, 2.12) 0.26 (0.11, 0.57)
24 2.4 (1.44, 4.02) 1.06 (0.58, 1.93) 0.44 (0.2, 0.95)
Other enzymes not involved in the prostaglandin and leukotriene pathways
100132327_TGI_at ADAM19 7 3.09 (2.1, 4.56) 0.91 (0.63, 1.32) 0.3 (0.18, 0.48)
24 2.43 (1.74, 3.39) 0.65 (0.44, 0.96) 0.27 (0.17, 0.42)
100133255_TGI_at MMP1 7 5.02 (3.08, 8.18) 1.12 (0.7, 1.77) 0.22 (0.12, 0.41)
24 2.66 (1.75, 4.04) 0.93 (0.57, 1.51) 0.35 (0.19, 0.62)
100141274_TGI_at MAP2K6 7 5.37 (3.69, 7.83) 1.36 (0.95, 1.95) 0.25 (0.16, 0.4)
24 1.46 (1.05, 2.04) 0.83 (0.57, 1.21) 0.57 (0.37, 0.88)
100145401_TGI_at MAOA 7 5.82 (4.1, 8.27) 1.51 (1.09, 2.11) 0.26 (0.17, 0.4)
24 2.2 (1.64, 2.97) 1.37 (0.97, 1.94) 0.62 (0.42, 0.93)
100148121_TGI_at GZMB 7 2.86 (1.84, 4.44) 0.56 (0.37, 0.85) 0.2 (0.11, 0.34)
24 1.77 (1.22, 2.59) 0.45 (0.29, 0.7) 0.25 (0.15, 0.42)
100300556_TGI_at MAP2K6 7 5.38 (3.68, 7.86) 1.25 (0.87, 1.8) 0.23 (0.15, 0.36)
24 1.51 (1.08, 2.11) 0.74 (0.51, 1.09) 0.49 (0.33, 0.74)
100301747_TGI_at ADAM19 7 1.13 (1.01, 1.27) 1.1 (0.99, 1.23) 0.98 (0.85, 1.12)
24 1.1 (1, 1.22) 0.93 (0.83, 1.04) 0.84 (0.74, 0.96)
100307745_TGI_at GZMB 7 2.78 (1.85, 4.19) 0.58 (0.4, 0.86) 0.21 (0.13, 0.35)
24 1.76 (1.24, 2.5) 0.48 (0.32, 0.72) 0.27 (0.17, 0.44)
100309438_TGI_at MAOA 7 3.25 (2.24, 4.74) 1.49 (1.05, 2.13) 0.46 (0.3, 0.71)
24 1.67 (1.2, 2.32) 1.03 (0.71, 1.5) 0.62 (0.41, 0.94)
100311427_TGI_at MAP2K6 7 6.43 (4.06, 10.18) 1.6 (1.04, 2.48) 0.25 (0.14, 0.45)
24 1.15 (0.76, 1.72) 0.69 (0.44, 1.1) 0.61 (0.34, 1.08)
Regulators of the inflammatory responses
100127993_TGI_at CISH 7 3.68 (2.84, 4.77) 1.16 (0.91, 1.48) 0.31 (0.23, 0.43)
24 1.66 (1.33, 2.08) 0.99 (0.76, 1.28) 0.6 (0.44, 0.8)
100149346_TGI_at SOCS2 7 4.04 (2.9, 5.61) 0.91 (0.67, 1.24) 0.23 (0.15, 0.35)
24 2.09 (1.58, 2.78) 0.89 (0.64, 1.23) 0.42 (0.28, 0.64)
100152491_TGI_at SOCS1 7 5.12 (3.82, 6.87) 1.69 (1.27, 2.24) 0.33 (0.24, 0.46)
24 1.7 (1.31, 2.2) 1.62 (1.21, 2.17) 0.95 (0.69, 1.31)
100309715_TGI_at SOCS1 7 1.29 (1.11, 1.49) 1.06 (0.92, 1.21) 0.82 (0.67, 1)
24 1.16 (1.02, 1.31) 0.98 (0.85, 1.14) 0.85 (0.7, 1.02)
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Th2 differentiation pathway is a major element of the
transcriptional response to the HDM challenge in
sputum and is down-regulated following response to
fluticasone treatment in the mild asthmatic atopic subjects
enrolled in this study. The implications of these results
are several-fold.
First, the screening of subjects for dual EAR and LAR
responses and the strong homogeneity of our results are
consistent with the concept of clustering of clinical asthma
phenotypes in which presence of eosinophilic infiltration
was identified as one of the key variables (33). Further-
more, clinical phenotypes of asthma have been linked to
molecular signatures and pathways in a study where Th2
‘high’ and ‘low’ phenotypes, characterised by differences
in airway responsiveness, eosinophilia and airway remo-
delling, could be differentiated at the molecular level (34).
The observed low variability and high effect size obtained
for the gene expression measurements in this study are
likely due to the careful selection of a homogeneous
allergic, corticosteroid responsive subject population
characterised by eosinophilic inflammation in response
to an allergen challenge.
Second, our results also suggest that gene expression
measurements collected in such an allergen challenge
platform could guide the development of novel quantita-
tive assays. For instance, one direct application of this
technology could be the quantification of the RNAs
that correlate the best with eosinophil numbers as a
surrogate to the standard sputum eosinophil cell count
assays. Another application of our technology would
be the selection of PD biomarkers of response to anti-
inflammatory treatment in asthma identified from a set of
markers that correlate with clinical endpoints.
The results presented here also raised important ques-
tions. We identified from our data set two mRNA levels
for IL-22 and IL-26, induced by the allergen challenge and
reverted to baseline by fluticasone, which have been
associated with the Th17 pathway. IL-22 is preferentially
produced by Th17 cells in psoriatic skin and medi-
ates the epithelium hyperplasia induced by IL-23 (35).
Table 2 (Continued )
Point estimate (90% confidence interval)
Probe set Gene symbol Houra
Fold change over baseline in
placebo group (P)
Fold change over baseline
in fluticasone group (F) F/P
Transcription factors
100128265_TGI_at NFATC2 7 2.46 (1.8, 3.36) 0.98 (0.73, 1.32) 0.4 (0.28, 0.56)
24 1.85 (1.4, 2.44) 0.75 (0.55, 1.03) 0.41 (0.29, 0.56)
100129588_TGI_at VDR 7 1.84 (1.52, 2.22) 0.99 (0.82, 1.18) 0.54 (0.42, 0.69)
24 1.23 (1.05, 1.45) 0.9 (0.74, 1.09) 0.73 (0.58, 0.93)
100130323_TGI_at NFATC2 7 1.09 (0.95, 1.24) 0.96 (0.84, 1.08) 0.88 (0.73, 1.06)
24 1.12 (1, 1.26) 0.98 (0.86, 1.12) 0.87 (0.73, 1.04)
100137898_TGI_at IRF4 7 5.15 (3.29, 8.07) 1.03 (0.67, 1.57) 0.2 (0.11, 0.35)
24 3.36 (2.29, 4.93) 0.81 (0.51, 1.27) 0.24 (0.14, 0.41)
100140089_TGI_at RUNX3 7 3.27 (2.46, 4.36) 1.05 (0.8, 1.37) 0.32 (0.23, 0.45)
24 2.46 (1.92, 3.14) 0.71 (0.53, 0.95) 0.29 (0.21, 0.4)
100150626_TGI_at NFATC2 7 2.44 (1.81, 3.29) 0.94 (0.71, 1.25) 0.38 (0.27, 0.55)
24 1.82 (1.4, 2.37) 0.72 (0.54, 0.98) 0.4 (0.28, 0.56)
100155853_TGI_at RUNX3 7 3.29 (2.37, 4.56) 1.08 (0.8, 1.48) 0.33 (0.23, 0.47)
24 2.48 (1.86, 3.31) 0.71 (0.51, 0.98) 0.29 (0.2, 0.4)
100162200_TGI_at GATA2 7 1.87 (1.58, 2.21) 0.99 (0.85, 1.16) 0.53 (0.41, 0.68)
24 1.1 (0.95, 1.26) 0.97 (0.82, 1.15) 0.89 (0.7, 1.12)
100163032_TGI_at VDR 7 3 (2.47, 3.65) 1.11 (0.92, 1.34) 0.37 (0.3, 0.47)
24 1.74 (1.47, 2.07) 0.88 (0.73, 1.08) 0.51 (0.41, 0.63)
100300539_TGI_at IRF4 7 4.28 (2.89, 6.35) 1.01 (0.7, 1.47) 0.24 (0.15, 0.38)
24 3.1 (2.21, 4.35) 0.85 (0.57, 1.26) 0.27 (0.17, 0.44)
100301491_TGI_at GATA2 7 11.34 (7.04, 18.29) 0.84 (0.54, 1.33) 0.07 (0.04, 0.14)
24 2.48 (1.64, 3.75) 0.42 (0.26, 0.68) 0.17 (0.09, 0.31)
A gene is listed in this table if it has at least one significant (two-sided a  0.10) probe set.
aHours post-allergen challenge.
P  allergen challenge effect: fold change over baseline in placebo group.
F  fold change over baseline in fluticasone group.
Fold change ] 4 over baseline in placebo group are indicated in bold.
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IL-26 is often co-expressed together with IL-17 and IL-22
by activation of Th17 cells; however, its function remains
to be further investigated. Despite the significance of IL-
22 and IL-26, we were however unable to detect any up or
down-regulation of the mRNA levels for IL-17A and
IL-17 F, as well as other genes associated with the Th17,
therefore providing more support to the concept of a
dominant Th2 response in this study.
Another question is whether the observed signature in
sputum is due to (i) changes in cell counts, in parti-
cular eosinophil cell counts since this cell type is pre-
dominantly increased in sputum following a segmental
allergen challenge, (ii) up- or down-regulation of messen-
gers within a given cell type, or (iii) a combination of the
above. The only way to address this question is to profile
individual cell types isolated from sputum; however, the
results from our analysis indicated some changes in gene
expression that were correlated with cell-type-specific
eosinophil cell counts and some that are not, therefore
supporting option (iii). On the one hand, we have
Fig. 6. Fold changes over baseline (point estimate and 90% confidence intervals) for the 47 RNA signatures. Red bars represent
the change from baseline in the placebo group and blue bars in the fluticasone group. p Values for the allergen challenge effect
(ACE) and the fluticasone treatment effect (FTE) are represented in red on the right hand side and in black on the left hand side,
respectively. P1: mRNA levels for Th2 cytokines; P2: chemokines and chemokine receptors; P3: FCERI and histamine
signalling; P4: enzymes and signalling molecules in prostaglandin, leukotriene pathways; P5: other mRNA levels for cytokines,
growth factors and their receptors; P6: other enzymes; P7: membrane-bound glycoproteins; P8: transcription factors; P9:
regulators of the inflammatory response.
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identified two genes IL1RL1 and HRH4 that correlate
extremely precisely with eosinophil cell counts (correlation
coefficients0.9, pB0.002) and are known to be ex-
pressed predominantly in eosinophils, basophils and mast
cells. RNAs for both genes therefore appear to be excellent
surrogates of eosinophil measurements in sputum. Inter-
estingly, polymorphisms in the HRH4 gene were found to
be associated with atopic dermatitis (36), while variants of
the IL1RL1 gene have been associated with atopic
dermatitis and atopic asthma (37). IL1RL1 is also
expressed on innate lymphoid cells which produce type 2
cytokines like IL-5 upon stimulation with IL-33 (38).
Given the important role that IL1RL1 has in eosinophil
function as a receptor for IL-33, this gene might therefore
also represent a promising drug target in inflammatory
diseases characterised by a strong eosinophilic component
correlating with disease symptoms. Then again, we
have identified from this study multiple examples of genes
that display similar expression pattern upon allergen
challenge and fluticasone treatment and which are known
to have very different cell type specificity. In particular,
chemokines CCL13 and CCL17 have a dendritic specific
expression while CCL26 is epithelial specific; similarly
CD1A and CD1B are T-cell specific markers. However, as
Table 3. Correlations between gene expression measurements from the 47 RNA signatures and various FEV1 measurements
Effect of interest Probe set Gene symbol Clinical endpoint
Correlation coefficient
(90% confidence interval) p
mRNA at hour 7 and clinical endpoint at hour 7
Allergen challenge effect 100150696_TGI_at NRG1 FEV1 Measure IIb 0.90 (0.98, 0.62) 0.002
100300593_TGI_at NRG1 FEV1 Measure IIb 0.83 (0.96, 0.44) 0.01
100124067_TGI_at CCR2 FEV1 Measure Ia 0.79 (0.95, 0.32) 0.02
100312593_TGI_at NRG1 FEV1 Measure Ia 0.77 (0.94, 0.28) 0.025
100161022_TGI_at CD1C FEV1 Measure IIb 0.77 (0.94, 0.27) 0.027
100303601_TGI_at CCR2 FEV1 Measure Ia 0.76 (0.94, 0.26) 0.027
100145467_TGI_at CD1C FEV1 Measure IIb 0.76 (0.94, 0.26) 0.027
100161022_TGI_at CD1C FEV1 Measure Ia 0.76 (0.94, 0.25) 0.03
100147484_TGI_at CCR2 FEV1 Measure IIb 0.75 (0.94, 0.24) 0.031
100300556_TGI_at MAP2K6 FEV1 Measure IIb 0.75 (0.94, 0.24) 0.03
100311406_TGI_at CD1C FEV1 Measure IIb 0.74 (0.93, 0.21) 0.036
100159528_TGI_at IL26 FEV1 Measure IIb 0.74 (0.93, 0.21) 0.036
100303601_TGI_at CCR2 FEV1 Measure IIb 0.74 (0.93, 0.20) 0.038
Fluticasone treatment effect 100135727_TGI_at CD1A FEV1 Measure IIb 0.87 (0.46, 0.97) 0.012
100127751_TGI_at NRG1 FEV1 Measure Ia 0.84 (0.97, 0.39) 0.017
100302360_TGI_at NRG1 FEV1 Measure Ia 0.84 (0.97, 0.37) 0.019
100155853_TGI_at RUNX3 FEV1 Measure Ia 0.77 (0.95, 0.19) 0.044
100302360_TGI_at NRG1 FEV1 Measure IIb 0.76 (0.95, 0.16) 0.049
100309572_TGI_at FLT3 FEV1 Measure Ia 0.75 (0.95, 0.16) 0.051
100133255_TGI_at MMP1 FEV1 Measure IIIc 0.74 (0.91, 0.34) 0.01
mRNA at hour 7 and clinical endpoint at hour 24
Allergen challenge effect 100148726_TGI_at CCL17 FEV1 Measure IIIc 0.80 (0.95, 0.36) 0.016
100133255_TGI_at MMP1 FEV1 Measure IIIc 0.74 (0.93, 0.22) 0.035
Fluticasone treatment effect 100145401_TGI_at MAOA FEV1 Measure IIIc 0.80 (0.27, 0.96) 0.031
100301747_TGI_at ADAM19 FEV1 Measure IIIc 0.80 (0.26, 0.96) 0.031
100127751_TGI_at NRG1 FEV1 Measure IIIc 0.75 (0.95, 0.14) 0.054
100155853_TGI_at RUNX3 FEV1 Measure IIIc 0.74 (0.94, 0.12) 0.058
100309572_TGI_at FLT3 FEV1 Measure IIIc 0.74 (0.94, 0.12) 0.058
mRNA at hour 24 and clinical endpoint at hour 24
Allergen challenge effect 100157709_TGI_at ALOX15 FEV1 Measure IIIc 0.77 (0.28, 0.94) 0.025
100149346_TGI_at SOCS2 FEV1 Measure IIIc 0.75 (0.94, 0.24) 0.031
a% Change in maximal drop of FEV1 during LAR.
b% Change in time weighed average of FEV1 during LAR.
c% Change in FEV1 at hour 24.
FEV1 measure I:% change in maximal drop of FEV1 during LAR; FEV1 measure II:% change in time weighed average of FEV1 during LAR;
FEVI measure III:% change in FEV1 at hour 24. Significant probe sets (pB0.1 and correlation coefficient0.73) are displayed.
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the expression of those genes is up-regulated by the
allergen challenge and down-regulated by fluticasone,
this suggests that the identified signature cannot be
explained uniquely by variations in eosinophil cell counts
or percentages and also reflects major transcriptional
changes in a large variety of cell types. An analysis of
the transcriptional signatures of isolated sputum cell
types in combination with the identification of transcrip-
tional modules of genes co-expressed in asthma as
previously described in blood (39) could map the relative
contribution of each gene and cell type to the inflamma-
tory response.
Finally, we also identified from our analysis a set of
RNAs that uniquely correlates with classical lung function
measurements. The majority of our signature genes was
strongly correlated with FEV1 and related to the ACE
(Table 2), contrasting the eosinophilic related genes for
which the majority is related to the fluticasone effect
(Table 3). The latter provides further evidence for the
observed strong relationship between sputum eosinophils
and corticosteroid response (34). At 7 h, chemokines or
chemokine receptors (CCL17 and CCR2) and membrane-
bound glycoproteins such as CD1C correlate to lung
function measurements. NRG1, the gene that most
Table 4. Correlations between the gene expression measurements from the 47 RNA signatures and eosinophils (cell counts and
percentages)
Effect of interest Probe set Gene symbol Clinical endpoint
Correlation coefficient
(90% confidence interval) p
mRNA at hour 7 and clinical endpoint at hour 7
Allergen challenge effect 100302783_TGI_at IL1RL1 Eosinophil counts 0.92 (0.70, 0.98) 0.001
100161010_TGI_at HRH4 Eosinophil counts 0.91 (0.67, 0.98) 0.002
100149346_TGI_at SOCS2 Eosinophil counts 0.91 (0.66, 0.98) 0.002
100312840_TGI_at IL1RL1 Eosinophil counts 0.88 (0.56, 0.97) 0.004
100301491_TGI_at GATA2 Eosinophil counts 0.87 (0.53, 0.97) 0.005
Fluticasone treatment effect 100148162_TGI_at IL1RL1 Eosinophil counts 0.98 (0.92, 1.00) B0.001
100312840_TGI_at IL1RL1 Eosinophil counts 0.98 (0.88, 1.00) B0.001
100302783_TGI_at IL1RL1 Eosinophil counts 0.97 (0.85, 0.99) B0.001
100142511_TGI_at CCL26 Eosinophil percentage 0.97 (0.84, 0.99) B0.001
100148726_TGI_at CCL17 Eosinophil percentage 0.96 (0.80, 0.99) B0.001
100161010_TGI_at HRH4 Eosinophil counts 0.96 (0.79, 0.99) B0.001
100134267_TGI_at CRLF2 Eosinophil percentage 0.93 (0.69, 0.99) 0.002
100135727_TGI_at CD1A Eosinophil percentage 0.92 (0.64, 0.98) 0.004
100148210_TGI_at IL1RL1 Eosinophil counts 0.90 (0.59, 0.98) 0.005
100157709_TGI_at ALOX15 Eosinophil counts 0.89 (0.52, 0.98) 0.008
100302151_TGI_at IL1RL1 Eosinophil counts 0.88 (0.52, 0.98) 0.008
100162200_TGI_at GATA2 Eosinophil percentage 0.88 (0.52, 0.98) 0.008
100125222_TGI_at IL13 Eosinophil percentage 0.88 (0.51, 0.98) 0.008
100163032_TGI_at VDR Eosinophil counts 0.88 (0.51, 0.98) 0.008
100302151_TGI_at IL1RL1 Eosinophil percentage 0.88 (0.50, 0.98) 0.009
100142202_TGI_at CD1B Eosinophil percentage 0.87 (0.48, 0.97) 0.01
100124660_TGI_at GGT5 Eosinophil counts 0.87 (0.46, 0.97) 0.011
100143473_TGI_at HDC Eosinophil counts 0.87 (0.46, 0.97) 0.012
mRNA at hour 7 and clinical endpoint at hour 24
Allergen challenge effect 100135727_TGI_at CD1A Eosinophil percentage 0.91 (0.65, 0.98) 0.002
100132327_TGI_at ADAM19 Eosinophil percentage 0.87 (0.55, 0.97) 0.004
100136515_TGI_at CD209 Eosinophil percentage 0.87 (0.53, 0.97) 0.005
Fluticasone treatment effect 100148210_TGI_at IL1RL1 Eosinophil counts 0.93 (0.67, 0.99) 0.003
100309438_TGI_at MAOA Eosinophil counts 0.92 (0.98, 0.64) 0.003
100309708_TGI_at PTGS1 Eosinophil counts 0.92 (0.65, 0.98) 0.003
100124660_TGI_at GGT5 Eosinophil counts 0.92 (0.63, 0.98) 0.004
100156386_TGI_at PTGS1 Eosinophil counts 0.89 (0.53, 0.98) 0.008
100302151_TGI_at IL1RL1 Eosinophil counts 0.88 (0.51, 0.98) 0.009
100136515_TGI_at CD209 Eosinophil percentage 0.88 (0.49, 0.97) 0.01
Significant probe sets (pB0.1 and correlation coefficients0.86) are displayed.
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significantly correlated to FEV1 measurements at 7 h, is a
member of the neuregulin family, which signals through
tyrosine kinases of the ErbB3 family. NRG1 induces the
expression of the globlet cell mucins MUC5AC and
MUC5B in human airway epithelium (40). Its inhibition
may therefore represent a novel therapeutic approach for
decreasing mucus hypersecretion in respiratory diseases.
It is known that repeated sputum inductions could lead
to a neutrophil, eosinophilic and IL-8 response, possibly
due to local changes in osmolarity and subsequent
Fig. 7. Correlation plots of the most significant probe sets to individual subject clinical measurements (sputum eosinophils and
pulmonary lung function tests) for the allergen challenge effect and the FP treatment effect. Correlation coefficients and
corresponding p values in parenthesis are listed in purple. HRH4: histamine receptor 4; IL1RL1: IL33 receptor; NRG1: neuregulin 1.
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epithelial mast cell activation (41). In our study, sputum
induction was performed at 22 h pre-allergen challenge
(day 1), and at 7 h (day 2) and 24 h (day 3) post-allergen
challenge. However, neutrophils (percentage) and IL-8
concentrations remained unchanged (7). Also, identical
sputum induction procedures were applied throughout
the study as previously described and validated (1, 42),
and differences between study periods in this cross-over
designed study were analysed, limiting the effect of
repeated sputum induction.
In conclusion, our RNA extraction and profiling
protocols allowed sensitive assessments of allergen-induced
inflammatory signatures in sputum and precise quantifica-
tion of drug effects on this response in allergic asthmatics.
This approach offers novel possibilities for the develop-
ment of pharmacodynamic biomarkers in asthma.
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